tirzepatide shortage ending FDA says years-long is resolved, will give limited leeway to compounders FDA says tirzepatide shortage is

Coverage for GLP-1s remains a key challenge for employers to navigate, as there is significant demand for the drugs that often come at a high cost

First-line agents for acute flares include the following: NSAIDs: reduce inflammation by inhibiting COX

NHS eligibility criteria include a BMI of at least 35 kg/m with weight-related comorbidities (or 30 kg/m for people from certain ethnic backgrounds), or a BMI 30 kg/m with type 2 diabetes

Label accuracy: Without a pre-market FDA review, theres no guarantee that whats listed on the label matches whats actually in the product

Skipping doses can disrupt your treatment, and understanding what happens when you stop semaglutide helps you weigh the risks of a treatment gap